Platelet BioGenesis is a pre-clinical stage biotech company that was spun out the academic labs of Drs. Italiano and Thon at Brigham and Women\'s Hospital and Harvard. In its quest to produce donor-independent human platelets from pluripotent stem cells, Platelet BioGenesis has developed and patented a microfluidic bioreactor and shown that functional platelets can be generated from human stem cell cultures at scale. The company was selected to participate in MassCONNECT (run by MassBio), was a 2014 MassChallenge Finalist, and has received support from the Massachusetts Life Sciences Center and the National Institutes of Health.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/17 | $10,000,000 | Series A |
Adena Partners eCoast Angel Network Qiming Venture Partners  Vi-Ventures Vivo Capital | undisclosed |
| 09/09/19 | $26,365,000 | Series A-1 |
eCoast Angel Network Nest.Bio Ventures Qiming Venture Partners Ziff Capital Partners | undisclosed |
